Entrada Therapeutics (TRDA)

• Market cap: $503M
• 1 day: 0.52%
• 5 days: 5.66%
• 1 month: -22.27%
• 3 months: -21.59%
• 6 months: -18.40%
• Year to date: -23.02%
• 1 year: -7.76%
• 5 years: -43.88%
• 10 years: -43.88%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.

Employees: 177

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

188% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 8

111% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 19

110% more call options, than puts

Call options by funds: $551K | Put options by funds: $262K

17% more funds holding

Funds holding: 83 [Q2] → 97 (+14) [Q3]

14% more capital invested

Capital invested by funds: $424M [Q2] → $481M (+$57.6M) [Q3]

0.88% more ownership

Funds ownership: 80.07% [Q2] → 80.94% (+0.88%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $20 49% upside
• Avg. target: $26 91% upside
• High target: $29 116% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Roth MKM Boobalan Pachaiyappan 50% 1-year accuracy 4 / 8 met price target	116% upside $29	Buy Initiated	5 Dec 2024
Oppenheimer Francois Brisebois 51% 1-year accuracy 19 / 37 met price target	108% upside $28	Outperform Maintained	6 Nov 2024
HC Wainwright & Co. Raghuram Selvaraju 41% 1-year accuracy 135 / 327 met price target	49% upside $20	Buy Maintained	6 Nov 2024